Navigation Links
GeoVax Presents Data at AIDS Vaccine 2008 Conference
Date:10/16/2008

ATLANTA, Oct. 16 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta based, publicly traded biopharmaceutical company specializing in the prevention and treatment of infectious diseases, presented data on their AIDS vaccine (trial HVTN 065) at the AIDS Vaccine 2008 conference, on October 15 in Cape Town, South Africa. This conference comes at an exciting time for GeoVax, which is preparing to enter Phase 2 trials for its vaccine.

The presentation, titled "Two HIV DNA Primes Maximize T Cell Responses Induced by the GeoVax DNA/MVA Vaccine Regimen Administered to Healthy Seronegative Adults (HVTN 065)," was given by Dr. Paul A. Goepfert, M.D., Associate Professor, Division of Infectious Diseases, Department of Medicine, University of Alabama. Dr. Goepfert is the HVTN 065 Protocol Team chair. The trial results reveal the GeoVax DNA and MVA vaccines are safe and immunogenic (stimulate anti-HIV/AIDS immune responses) at both low (1/10th) dose and full doses. Other highlights included:

-- GeoVax vaccines were well tolerated with no or mild local and systemic reactions in the majority of trial participants.

-- 80 percent of both the low and full dose trial participants responded to the vaccine which stimulated anti-HIV T-cell (white blood cell) and antibody responses.

-- More volunteers had antibody responses to the full dose than to the 1/10th dose vaccine, whereas response rates for T cells were similar for the 1/10th and full dose.

-- Two DNA primes were more effective than one DNA prime or no DNA primes at eliciting T cell responses.

-- The 2nd MVA vaccination positively increased CD8 T cell and antibody responses.

"As the entire world tries to find a solution for the HIV/AIDS crisis, GeoVax, a front runner in the search for an effective vaccine, is on the verge of entering Phase 2 trials," said Bob McNally, CEO and President of GeoVax Labs, Inc. "The AIDS Vaccine 2008 conference is a
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
7. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
9. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
10. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
11. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... (PRWEB) October 21, 2014 The North ... concerned market North America with analysis and forecast of ... 2013, and is expected to reach $623.6 million by ... 2018. , Browse through the TOC of the North ... of the in-depth analysis provided. This also provides a ...
(Date:10/22/2014)... CA (PRWEB) October 22, 2014 ... from Sartorius, A & D Weighing, Rice Lake, ... CPA Semi-Micro Balance . The Sartorius CPA Semi-Micro ... an affordable high-quality, precise, and user-friendly laboratory balance. ... of laboratory equipment, their laboratory balances are well ...
(Date:10/22/2014)... Md. , Oct. 22, 2014   Synthetic ... developing novel pathogen-specific therapies for serious infections and diseases, ... has issued a Notice of Allowance for a composition ... its C. difficile program, SYN-004. This is ... SYN-004 in the U.S. and adds to the Company,s ...
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 2Pipette.com Launches the Addition of Sartorius CPA Semi-Micro Balance to Their Product Portfolio with Special Promotional Pricing 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3
... Ohio State University researchers have developed a new method ... They are using this simple, fast, and low-temperature process ... industrial chemicals (TICs) and biological warfare agents. The ... the journal Materials Chemistry and Physics . ...
... series of successful preclinical studies, researchers at MassBiologics of the ... of a Phase 1 clinical trial, testing the safety and ... neutralize the Hepatitis C virus (HCV). , The ... 28, 2009, and the study is now proceeding and will ...
... , , EMERYVILLE, Calif., Aug. 14 ... ), a clinical stage biopharmaceutical company developing first-in-class anti-infective products for ... causing resistance, reported today its financial results and operational highlights for ... , , License and collaboration revenue for the ...
Cached Biology Technology:New way to make sensors that detect toxic chemicals 2New way to make sensors that detect toxic chemicals 3First human gets new antibody aimed at hepatitis C virus 2NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 2NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 3NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 4NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results 5
(Date:10/16/2014)... 2014 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market ... Wocket™, the Smart Wallet, at the 13 th ... leading global conference on the intersection of technology and ... Anderson , founder and publisher of the Strategic News ...
(Date:10/15/2014)... University Mainz (JGU) as a full member, ensuring ... a significant nationwide standing in the field of ... Gutenberg University Mainz as a full member of ... and international competition for the best minds and ... proud that Mainz University has been recognized as ...
(Date:10/15/2014)... Rosenstiel Award for Distinguished Work in Biomedical Science by ... of genomic instability and its implications for the immune ... to win the Rosenstiel Award; the first, Rod McKinnon, ... the Charles A. Janeway Professor of Pediatrics and Professor ... at the Howard Hughes Medical Institute at Boston Children,s ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... (Washington, DC Nov. 20, 2009) Scientists from ... the Naval Research Laboratory (NRL) organized and led a ... expedition to initiate methane hydrate exploration in the Beaufort ... to Arctic climate change. Utilizing the U.S. Coast ...
... in parking lots may be the culprit in contaminated house ... polycyclic aromatic hydrocarbons are large molecules found in oil, ... long been known that PAHs are often found in house ... undetermined. Researchers found that dust from indoor areas near parking ...
... release is available in German . ... Journal of Clinical Investigation , Dr. Stefanie Eyerich and ... College London and Istituto Dermopatico dell,Immacolata in Rome, present ... way to developing new treatment methods for inflammatory skin ...
Cached Biology News:International expedition investigates climate change, alternative fuels in Arctic 2From toxic dust and algae to ill winds from Africa 2From toxic dust and algae to ill winds from Africa 3From toxic dust and algae to ill winds from Africa 4From toxic dust and algae to ill winds from Africa 5Discovery of new type of immune cells regulating inflammation in chronic diseases 2
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Jak3 Antibody Ship: Hot Store: -20 C...
14-3-3 tau Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: